Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$0.96 USD
+0.01 (1.43%)
Updated Jul 25, 2024 04:00 PM ET
2-Buy of 5 2
F Value C Growth B Momentum D VGM
Karyopharm Therapeutics (KPTI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$5.07 | $8.00 | $2.00 | 428.13% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Karyopharm Therapeutics comes to $5.07. The forecasts range from a low of $2.00 to a high of $8.00. The average price target represents an increase of 428.13% from the last closing price of $0.96.
Analyst Price Targets (7 )
Broker Rating
Karyopharm Therapeutics currently has an average brokerage recommendation (ABR) of 1.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.43 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 71.43% and 14.29% of all recommendations. A month ago, Strong Buy made up 71.43%, while Buy represented 14.29%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.43 | 1.43 | 1.43 | 1.43 | 1.43 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/3/2024 | H.C. Wainwright & Co. | Edward White | Strong Buy | Strong Buy |
5/8/2024 | SVB Securities | Jonathan W Chang | Hold | Hold |
4/22/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
3/4/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/1/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
11/3/2023 | Robert W. Baird & Co. | Colleen M Kusy | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.43 |
ABR (Last week) | 1.43 |
# of Recs in ABR | 7 |
Average Target Price | $5.07 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 96 of 252 |
Current Quarter EPS Est: | -0.29 |